Ischemia-modified albumin as an oxidative stress biomarker in obesity

Can

Arch. Endocrinol. Metab.

et al. 2015

Objective: Oxidative damage may be responsible for the pathogenesis and complications of many diseases. Vitamin D deficiency has been suggested as a potential mediator of various extra-skeletal pathologies. However, there are limited data on anti-oxidant properties of vitamin D. Materials and methods: Forty-one subjects with vitamin D deficiency and 30 healthy controls were enrolled into the study. The levels of total anti-oxidant status (TAS), total oxidant status (TOS), ischemia-modified albumin (IMA), oxidized-low density lipoprotein (ox-LDL), highsensitivity C-reactive protein (hs-CRP) and fibrinogen were measured in both groups. The measurements were repeated in 17 patients after the replacement of vitamin D. Results: Serum IMA and TOS levels were significantly higher (p < 0.001 and p = 0.035, respectively), while TAS levels were significantly lower in patients, compared to controls (p < 0.001). Additionally, fibrinogen was significantly higher in patients than controls (p = 0.003), while ox-LDL and hs-CRP levels were similar between two groups. After the replacement of vitamin D, TAS level significantly increased (p = 0.037), and TOS and fibrinogen levels significantly decreased (p = 0.043 and p = 0.010, respectively). Vitamin D levels were negatively correlated with IMA and fibrinogen levels (r = -0.500, p < 0.001 and r = -0.391, p = 0.002, respectively), although positively correlated with TAS levels (r = 0.430, p < 0.001). No correlation was found between vitamin D levels, and the TOS, ox-LDL and hs-CRP levels. Conclusions: In this study, while serum IMA, TOS and fibrinogen levels were increased, TAS levels were seen to be decreased in patients with vitamin D deficiency. These results suggest that oxidative/anti-oxidative balance shifts in favours of oxidative status in vitamin D deficiency. Arch Endocrinol Metab. 2015;59(4):318-24

Section: Discussionmentioning

confidence: 86%

Serum total oxidant/anti-oxidant status, ischemia-modified albumin and oxidized-low density lipoprotein levels in patients with vitamin D deficiency

Can

Arch. Endocrinol. Metab.

et al. 2015

“…Since other diseases that are closely associated with changes in serum lipids also appear to demonstrate increased IMA (e.g., metabolic syndrome and obesity), there may be a specific link between these features in causing disease (13,14). This observation is emphasized by the fact that patients with pure hypercholesterolemia have increased IMA (12).…”

Section: Discussionmentioning

confidence: 91%

“…Individuals with hypercholesterolemia demonstrate increased IMA in addition to increased low-density lipoproteins (LDL) (12). Similarly, in cases of obesity or metabolic syndrome, an altered lipid metabolism and an increased IMA are often observed together (13,14). Notably, ACVD patients have been known to exhibit complications of abnormal lipid metabolism (15).…”

Section: Introductionmentioning

confidence: 99%

Correlation between ischemia-modified albumin and lipid levels in patients with acute cerebrovascular disease

et al. 2012

Abstract. Acute cerebrovascular disease (ACVD) is associated with high morbidity and mortality rates, however, molecular markers to aid in its early detection are lacking. In this study, we examined the correlation between serum ischemia-modified albumin (IMA), a marker used to identify ischemic events in the heart, and blood lipids in patients with ACVD. Serum IMA levels were determined by enzyme-linked immuno sorbent assay, and total cholesterol (TC), low-density lipoprotein (LDL), high-density lipoprotein cholesterol (HDL) and triglyceride (TG) levels were determined biochemically in 62 patients with cerebral infarction (CI), 40 patients with intracerebral hemorrhage (ICH), 18 patients with subarachnoid hemorrhage (SAH) and 100 healthy individuals (controls). Serum IMA levels were significantly higher in each of the ACVD groups compared to the control group (CI, 80.81±11.97 U/ml; ICH, 80.25±10.91 U/ml; SAH, 74.43±11.39 U/ml and control, 41.08±5.10 U/ml; P<0.05). Additionally, serum TC, LDL and TG levels significantly increased, while serum HDL significantly decreased in the ACVD groups compared to the control group (P<0.05). A positive correlation was found between serum IMA levels and serum TC, LDL and TG levels in the ACVD patients, while serum IMA levels were negatively correlated with serum HDL levels (P<0.05). Thus, serum IMA increased following an ACVD event and was closely correlated with changes in the blood lipid levels. These factors, when combined, may allow the development of molecular markers for an earlier diagnosis of ACVD.

“…IMA is currently used as an early marker for myocardial ischemia and acute coronary syndrome [16]. It is also increased in diabetes mellitus, hyperlipidemia, chronic renal disease and obesity [17][18][19][20]. The constriction of vessels due to atherosclerotic lesions causes hypoxia/ischemia and oxidative changes resulting in transformation of free albumin to IMA in the circulation [21,22].…”

Section: Introductionmentioning

confidence: 99%

Ischemia-modified albumin as a marker of vascular dysfunction and subclinical atherosclerosis in β-thalassemia major

et al. 2017

Background: Ischemia-modified albumin (IMA) is an altered type of serum albumin that forms under conditions of oxidative stress and an independent predictor of major adverse cardiovascular events. Objectives: To measure the levels of IMA in 45 children and adolescents with β-thalassemia major (β-TM) compared with 30 healthy controls and assess its relation to lipid peroxidation, vascular complications and subclinical atherosclerosis. Methods: β-TM patients without symptoms of heart disease were studied focusing on transfusion history, chelation therapy, serum ferritin, malondialdehyde (MDA) and IMA levels. Echocardiography was performed and carotid intima media thickness (CIMT) was assessed. Results: IMA and MDA levels were significantly higher in β-TM patients compared with controls (p < 0.001). IMA was higher among patients with heart disease, pulmonary hypertension risk and serum ferritin ≥2500 µg/l than those without. TM patients compliant to chelation had significantly lower IMA levels. IMA levels were positively correlated to MDA and CIMT while negatively correlated to ejection fraction and fractional shortening. Conclusion: Our results highlight the role of oxidative stress in the pathophysiology of vascular complications in thalassemia. IMA could be useful for screening of β-TM patients at risk of cardiopulmonary complications and atherosclerosis because its alteration occurs in early subclinical disease.